Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is Investigating Claims on Your Behalf
Grabar Law Office is investigating whether certain officers and directors of Akero breached their fiduciary duties owed to the company.
If you have held Akero Therapeutics, Inc. (NASDAQ: AKRO) shares since prior to September 13, 2022, you can seek corporate reforms, the return of money back to the company, and a court approved monetary award at no cost to you whatsoever. You are encouraged to learn more about the investigation and your rights by visiting https://grabarlaw.com/the-latest/akero-shareholder-investigation/. You can also contact Joshua Grabar at [email protected] or call 267-507-6085.
WHY: A recently filed underlying securities fraud class action Complaint alleges that Akero Therapeutics, via certain of its officers and directors, made false and/or misleading statements and/or failed to disclose to the investing public that: (i) approximately 20% of the patients enrolled in its SYMMETRY study had cryptogenic cirrhosis and did not have definitive NASH at baseline; (ii) the cryptogenic cirrhotic patients included in the SYMMETRY study did not have biopsy-proven compensated cirrhosis due to definitive NASH; (iii) the results from the cryptogenic cirrhosis patients were to be excluded from the calculation of the NASH resolution secondary endpoints; (iv) Akero had introduced a confounding factor into the SYMMETRY study's design, materially influencing the study's potential results and increasing the risks that the study would fail to meet its primary endpoint; (v) the SYMMETRY study did not align with U.S. Food & Drug Administration guidance for testing a drug in treating NASH cirrhotics because Akero had not ruled out potential causes of each patient's cirrhosis other than NASH; and (vi) consequently, Akero had materially misrepresented the nature of the SYMMETRY trial, its usefulness in supporting any new drug application, the likelihood that the SYMMETRY trial would be successful as measured by its primary endpoint, and the likelihood that EFX would become a commercial treatment for NASH cirrhotics.
WHAT YOU CAN DO NOW: Current Akero shareholders who have held Akero shares since on or before September 13, 2022, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them whatsoever.
If you would like to learn more about this matter, please visit https://grabarlaw.com/the-latest/akero-shareholder-investigation/, contact Joshua Grabar at [email protected] or call us at 267-507-6085. $AKRO #Akero
Driven Brands Holdings, Inc. (NASDAQ: DRVN) Class Action Survives Motion to Dismiss:
A securities fraud class action complaint against Driven Brands Holdings, Inc. (NASDAQ: DRVN) has survived defendants, attempts to dismiss the complaint. Grabar Law Office is now investigating claims on behalf of long-term Driven Brands shareholders. The investigation concerns whether certain officers of the company have breached their fiduciary duties they owed to the company.
If you have held Driven Brands (NASDAQ: DRVN) shares continuously since prior to October 27, 2021, you can seek corporate reforms, the return of funds back to the Company, and a court approved incentive award at no cost you. Visit https://grabarlaw.com/the-latest/driven-brands-shareholder-investigation/ or contact Joshua H. Grabar at [email protected] or call 267-507-6085 to learn more.
WHY: An underlying securities fraud class action complaint alleges that Driven Brands, through certain of its officers and directors, made numerous materially false and misleading statements and omissions pertaining to: (i) Driven Brands' ability to efficiently and effectively integrate a high volume of acquired businesses, including statements related to the status of integrating its U.S. auto glass businesses; and (ii) the performance and competitive position of Driven Brands' car wash business segment.
On February 20, 2025, a Federal Court determined that the allegations in the plaintiff's underlying securities fraud class action complaint were adequately pleaded to survive defendants attempts to dismiss the complaint.
WHAT TO DO NOW: If you are a current Driven Brands shareholder who has held Driven Brands shares since prior to October 27, 2021, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. If you would like to learn more about this matter, you are encouraged to visit https://grabarlaw.com/the-latest/driven-brands-shareholder-investigation/, contact Joshua H. Grabar at [email protected] or call 267-507-6085. $DRVN #DrivenBrands
Integra LifeSciences Holdings Corp. (NASDAQ: IART):
Grabar Law Office is investigating whether the Board of Directors of Integra LifeSciences Holdings Corp. (NASDAQ: IART) breached their fiduciary duties owed to the Company.
Current Integra LifeSciences Holdings Corp. (NASDAQ: IART) shareholders who have held the stock since on or before March 11, 2019, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them. Learn more or join at: https://grabarlaw.com/the-latest/intrga-lifesciences-shareholder-investigation/. Contact Joshua H. Grabar at [email protected], or call 267-507-6085.
WHY: An underlying securities fraud class action complaint alleges that Integra, via certain of his officers and directors, repeatedly touted that it was on track to grow SurgiMend's market by obtaining FDA approval for use in post-mastectomy reconstruction, yet on May 23, 2023, the Company was forced to announce a 'recall' of all products manufactured at its Boston Facility between March 1, 2018 and May 22, 2023. Integra LifeSciences explained that it had determined that the Boston Facility deviated from good manufacturing practices in testing for bacterial endotoxin and allowed the release of products with unsafe levels of endotoxins. As a result of the recall and manufacturing shutdown, the Company revised its guidance for the second quarter of 2023, lowering its revenue expectations by and disclosed that it expected to take a $22 million impairment due to the inventory write-off.
WHAT TO DO NOW: Current Integra LifeSciences shareholders who have held Integra LifeSciences shares since on or before March 11, 2019, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them.
If you would like to learn more about this matter, you are encouraged to visit https://grabarlaw.com/the-latest/intrga-lifesciences-shareholder-investigation/, contact Joshua H. Grabar at [email protected], or call us at 267-507-6085. $IART #IntegraLifeSciences
Kyverna Therapeutics, Inc. (NASDAQ: KYTX):
Grabar Law Office is investigating claims on behalf of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) shareholders. The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.
If you are a current Kyverna (NASDAQ: KYTX) shareholder who purchased Kyverna shares on or near its February 8, 2024 IPO and still hold shares today, you may be able to seek corporate reforms, the return of money back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/kyverna-shareholder-investigation/, contact Joshua Grabar at [email protected] or call us at 267-507-6085
Why? On February 8, 2024, Kyverna Therapeutics, Inc. (NASDAQ: KYTX) conducted its IPO, offering 14.5 million shares of its common stock to the public at a price of $22 per share for anticipated proceeds of over $296 million. Kyverna granted the Underwriter Defendants a 30-day option to purchase up to an additional 2.175 million shares of its common stock at the Offering Price, less underwriting discounts and commissions.
An underlying securities fraud class action complaint alleges that the registration statement and prospectus issued in connection with the Company's IPO misstated and/or omitted facts concerning the results of the Company's ongoing evaluation of KYV-101 in clinical trials. The Complaint further alleges that unbeknownst to investors, these representations were materially inaccurate, misleading, and/or incomplete because they did not disclose adverse data regarding one of Kyverna's trials, which adverse data was known to the Company at the time of the IPO.
What Can You Do Now? If you purchased Kyverna (NASDAQ: KYTX) on or near its February 8, 2024 IPO and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/kyverna-shareholder-investigation/, contact Joshua Grabar at [email protected]
Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Amazon Founder Jeff Bezos Loses $17 Billion Following Company's Mixed Q2 Earnings
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Jeff Bezos, the founder and Executive Chairman of Inc. (NASDAQ:AMZN), saw his net worth take a plunge, alongside the shares of his company, following its second quarter results last week. What Happened: The fourth-richest man in the world, with a net worth of $237 billion, according to the Bloomberg Billionaires Index, lost $17 billion last week on Friday, from $254 billion the prior day, after investors were unimpressed with the company's second-quarter earnings. The stock was down 8.27% on Friday, following the company's results, despite it beating consensus estimates on sales and earnings. Don't Miss: 7,000+ investors have joined Timeplast's mission to eliminate microplastics— This AI-Powered Trading Platform Has 5,000+ Users, 27 Pending Patents, and a $43.97M Valuation — You Can Become an Investor for Just $500.25 This was largely attributed to the slowing momentum in the company's AWS cloud computing segment, which generated $10.2 billion in sales during the quarter, up 17.5% year-over-year, which fell short of consensus estimates at 20%. Amazon shares currently constitute a significant chunk of Bezos' net worth, with 884 million shares, or 8.3% of total shares outstanding, which, at the stock's current market price, is valued at $190 billion. The rest of his fortune comprises Blue Origin, his space exploration company, which, being privately held, is valued at the cost of investment. Why It Matters: According to analyst Eric Allen of Stealth, the market's reaction to the company's earnings was 'totally wrong,' since this was a capacity issue, with Amazon unable to meet the growing demand for its AWS computing resources. Amazon reported $167.7 billion in sales during the quarter, up 13% year-over-year, and ahead of consensus estimates at $161.9 billion. It posted a profit of $1.68 per share, which again beat analyst consensus estimates at $1.30. Bezos has been consistently offloading his stake in the company he founded, having sold 95 million shares in 2024 and 2025 so far, with net proceeds of $18.2 billion. Read More: $100k+ in investable assets? Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes – no cost, no obligation. If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? Photo courtesy: Shutterstock This article Amazon Founder Jeff Bezos Loses $17 Billion Following Company's Mixed Q2 Earnings originally appeared on Sign in to access your portfolio
Miami Herald
21 minutes ago
- Miami Herald
Palantir's blockbuster results sparks stock surge
Concerns were raging earlier this year that the artificial intelligence revolution was overhyped and AI stocks were due for a reckoning. It certainly felt like that were true this spring, when stocks got battered amid worries over peak AI spending and growing fear that the US economy was destined for recession. The risk-off environment led to a 24% drop in the technology-laden Nasdaq, and even bigger losses for individual stocks like Palantir Technologies, which tumbled 47% from its February peak to April's low. Don't miss the move: Subscribe to TheStreet's free daily newsletter Those concerns, however, have yet to materialize, and stocks, including Palantir, have produced substantial returns since April 8. The Nasdaq has rallied nearly 40% and Palantir, which is increasingly being viewed as an AI lynchpin, has seen its stock price more than double. The reality is that while concerns remain, there's little to suggest that companies are tapping their brakes on AI investments, and Palantir's latest quarterly results and guidance suggest spending strength will continue to prop up its business this year. The first wave of AI development centered on large language models, or chatbots, that could digest huge data sets and parse data based on user questions, including OpenAI's ChatGPT, Anthropic's Claude, Perplexity, and Google's Gemini. The spending on network infrastructure to support creating those chatbots was enormous, with hundreds of billions flowing out of enterprises and cloud service providers, including hyperscalers, to buy semiconductor chips from Nvidia and servers from Super Micro and Dell. Related: Major analyst who forecast stocks' rally sends 3-word message to investors While that spending is likely to continue, R&D is increasingly shifting to the second wave of AI -- solutions like agentic AI that can be used to assist and in some cases replace workers across industries. Developing those AI apps, however, isn't easy, especially since it requires breaking down data silos to find solutions securely. To do that, companies need help, and increasingly, they're turning to Palantir's Artificial Intelligence Platform. Palantir's (PLTR) roots stretch back to the early 2000s, when the Peter-Thiel founded company was tasked with securing data for the Defense Department. It still does a ton of work for the government, but recently, its seen explosive demand for AIP within companies using Palantir's Foundry platform. As a result, Palantir's sales and earnings are surging. The company's second quarter earnings results show solid and growing demand for its service. Palantir's revenue jumped 48% year-over-year to $1 billion, $61 million better than Wall Street was expecting. As a result, earnings per share (EPS) increased to 16 cents per share, 2 cents higher than analysts forecast, and up 78% from one year ago thanks to improving profit margins. Related: Apple CEO drops bombshell about its future Government deals contributed to the revenue beat, but the real shining star during the quarter was demand from corporations. US sales were up 68% from last year, reaching $733 million. US government revenue rose 53% to $426 million, while commercial revenue surged 93% to $306 million. "It's a blowout across the board. I mean, look, that's why they're the Messi of AI, right? I mean, it just speaks to, this is transformational, the type of growth they're seeing," said Wedbush Securities influential technology analyst Dan Ives on Yahoo!Finance. "I've covered tech 25 years. This is unprecedented territory. It speaks to our view. It's a trillion dollar market cap in the next two to three years." The company closed contracts worth a record $2.27 billion, including commercial deals worth $843 million, up 222% from one year ago. Net income of $327 million helped its cash and investment securities stockpile grow to above $6 billion from about 5.2 billion coming into the year. That's a lot of financial flexibility, especially given that the company is debt free. The growth rate of our business has accelerated radically, after years of investment on our part and derision by some," said CEO Alex Karp. "The skeptics are admittedly fewer now, having been defanged and bent into a kind of submission. Yet we see no reason to pause, to relent, here." The company's CEO, Alex Karp, expects the good times to not only continue but accelerate. Palantir raised its full year revenue guidance to between $4.142 billion and $4.15 billion. Consensus analyst forecasts were targeting $3.9 billion. For a startup, even one only a thousandth of our size, this growth rate would be striking," said Karp. "For a business of our scale, however, it is, we continue to believe, nearly without precedent or comparison." Palantir expects commercial deals to continue to be the big driver, guiding for US commercial revenue of $1.3 billion, up at least 85%. Palantir is also targeting adjusted income from operations of $1.912 billion to $1.92 billion and it raised its adjusted free cash flow guidance to between $1.8 billion to $2 billion. Overall, it expects to remain profitable throughout 2025. Currently, Wall Street consensus targets full year EPS of 58 cents, up from 55 cents ninety days ago. It wouldn't be surprising to see those earnings estimates climb more in the coming days following the updated guidance. Following the second-quarter results, Palantir's shares are up 4.6% to $168, a new all-time high. That move isn't going to let those concerned about the company's valuation sleep any better. Palantir was already trading with a forward price to earnings ratio (a key valuation measure) of 276, making it among one of priciest stocks out there. For comparison, the S&P 500's forward P/E is 22.4. Technology stocks often command higher than normal valuations, but even the price to sales ratio is arguably stretched, given shares are trading at about 123 times sales. Given that backdrop, Palantir is arguably priced to perfection, so it will need to continue to put up similarly eye-popping growth from here to keep investors happy. Todd Campbell owns Palantir shares. Related: Nvidia AI outlook resets after Meta Platforms, Microsoft update plans The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Yahoo
2 hours ago
- Yahoo
Should You Buy Nvidia Stock Before Aug. 27? Here's What the Evidence Suggests.
Key Points After more than two years of phenomenal gains, investors are wary about the future of AI. Nvidia's GPUs are a staple in the AI revolution, and sales continue at a brisk pace. There's a growing body of evidence that suggests Nvidia's epic run will continue, as will the stocks volatility. 10 stocks we like better than Nvidia › The dawn of artificial intelligence (AI) in late 2022 has had a profound impact on the technology landscape. The initial fervor has since died down, and investors are looking for compelling evidence that the adoption of AI has room to run. Nvidia (NASDAQ: NVDA) graphics processing units (GPUs) were widely adopted and have become the gold standard for generative AI. The company is scheduled to release the results of its fiscal 2026 second quarter after the market closes on Wednesday, Aug. 27, and Wall Street and shareholders alike will be sitting on the edge of their seats looking for clues that strong demand for AI chips continues. Let's look at the company's most recent results, what current events suggest about the future, and determine if Nvidia stock still represents a compelling opportunity heading into the company's highly anticipated financial report. Remarkable results After generating triple-digit revenue and profit growth for two consecutive fiscal years, growth inevitably slowed, and investors got the jitters. Despite tough year-over-year comps, Nvidia's results were still enviable. For its fiscal 2026 first quarter (ended April 27), Nvidia reported record revenue of $44.1 billion, which soared 69% year over year and 12% sequentially. This resulted in adjusted earnings per share (EPS) of $0.81, up 33%, but there's an asterisk on those numbers. Nvidia took a $4.5 billion writedown on H20 chips destined for China, because of the Trump administration's moratorium on AI chip sales in that country (which has since been lifted). Without that charge, EPS would have been $0.96, a 57% increase. Make no mistake: It was the continuing adoption of AI that drove the robust results, as revenue from Nvidia's data center segment climbed 73% to $39 billion, representing 89% of its total revenue. Management expects Nvidia's growth spurt to continue, albeit at a more moderate pace. For its fiscal 2026 second quarter (ended July 27), management is guiding for revenue of $45 billion, which would represent year-over-year growth of 50%. Wall Street is equally bullish, with analysts' consensus estimates calling for revenue of $45.68 billion and adjusted EPS of $1.00. While this would represent a minor slowing compared with last quarter's robust growth, it would still be remarkable nonetheless. Same customers, expanding opportunity The biggest concern among Nvidia investors is that the adoption of AI will hit a wall, but there's simply no evidence to back that assertion. In fact, all the available evidence suggests the proliferation of AI continues. Amazon Web Services, Microsoft Azure, and Alphabet's Google Cloud, are collectively known as the "Big Three" in cloud computing, and each has recently revealed plans to increase infrastructure spending this year, beyond the already robust spending that was previously announced. Furthermore, most of that spending will be allocated to additional data centers to support the growing demand for AI -- most of which will run on Nvidia GPUs. In addition, Meta Platforms also announced that it was increasing its capital expenditure spending plans for the year. The totals are enlightening: Amazon: $118 billion, up from $100 billion. Microsoft: $100 billion, up from $80 billion. Alphabet: $85 billion, up from $75 billion. Meta: $69 billion, up from $62.5 It's no coincidence that these four companies are also Nvidia's biggest customers. Add to that the resumption of H20 chip sales and China, and it appears clear that Nvidia's AI opportunity continues to expand. Should you buy the stock before Aug. 27? To be clear, I expect Nvidia stock to remain volatile, driven by the inevitable ebbs and flows of AI spending. That said, its success thus far has been undeniable. Over the past three years, the stock has gained 882% (as of this writing) but has also fallen as much as 37% -- so it isn't for the faint of heart. This helps illustrate one of the hallmarks of investing success: Treat buying stocks as partial ownership in a business, own stocks in the best companies out there, and commit to holding for at least three to five years. That takes us back to the main question: Should you buy Nvidia stock before Aug. 27? The unspoken question here is whether Nvidia stock will be up or down following the release of its highly anticipated quarterly report. Truth be told, I have no idea, nor does anyone else for that matter. My crystal ball has been on the blink for some time, but if I were in the mood to prognosticate, I would feel comfortable making several very vague predictions: Nvidia will announce yet another in a long and growing series of quarterly revenue records. Given the company's track record of exceeding expectations, I suspect it will beat analysts' consensus estimates, which are calling for sales of $45.68 billion -- which is slightly ahead of management's guidance of $45 billion -- and adjusted EPS of $1.00. Beyond that, it's anyone's guess, and my predictions could be way off base. That said, I'm still extremely confident that my investing thesis for Nvidia remains intact. The company's cutting-edge GPUs are still the gold standard, driving the AI revolution, and rivals have yet to challenge its position as the undisputed market leader or come up with a superior product. The specter of competition remains, as there's always the possibility that a technological innovation could steal Nvidia's thunder. Most experts agree that it's still early innings for AI, but there's no consensus about the size of the market. Even the most conservative estimates start at $1 trillion. Big Four accounting firm PwC estimates the total economic impact at $15.7 trillion between now and 2030. The truth is nobody knows for sure. Nvidia stock is currently selling for roughly 30 times next year's earnings. However, that premium is backed by the company's track record of innovation, industry-leading position, and history of growth. This underpins my confidence that the runway ahead is long. For those who believe that the AI revolution will play out over the next decade and Nvidia will maintain its position as the leading provider of AI chips, the answer is clear. We don't know what the stock will do between now and Aug. 27 and for long-term investors, that doesn't matter. We'll simply buckle up for the bumpy (and profitable) ride ahead. Do the experts think Nvidia is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Nvidia make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,019% vs. just 178% for the S&P — that is beating the market by 841.12%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Danny Vena has positions in Alphabet, Amazon, Meta Platforms, Microsoft, and Nvidia. The Motley Fool has positions in and recommends Alphabet, Amazon, Meta Platforms, Microsoft, and Nvidia. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Should You Buy Nvidia Stock Before Aug. 27? Here's What the Evidence Suggests. was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
